title: Agonist potency at P2X7 receptors is modulated by structurally diverse lipids.
abstract: OBJECTIVE
  The P2X(7) receptor exhibits a high degree of plasticity with agonist potency increasing after prolonged receptor activation. In this study we investigated the ability of lipids to modulate agonist potency at P2X(7) receptors.
  
  
  METHODS
  A variety of lipids, including lysophosphatidylcholine, sphingosylphosphorylcholine and hexadecylphosphorylcholine were studied for their effect on P2X(7) receptor-stimulated ethidium bromide accumulation in cells expressing human recombinant P2X(7) receptors and on P2X(7) receptor-stimulated interleukin-1 beta (IL1 beta) release from THP-1 cells. The effects of the lipids were also assessed in radioligand binding studies on human P2X(7) receptors.
  
  
  RESULTS
  At concentrations (3-30 microM) below the threshold to cause cell lysis, the lipids increased agonist potency and/or maximal effects at P2X(7) receptors in both ethidium accumulation and IL1 beta release studies. There was little structure activity relationship (SAR) for this effect and sub-lytic concentrations of Triton X-100 partially mimicked the effects of the lipids. The lipids caused cell lysis and increased intracellular calcium at higher concentrations (30-100 microM) which complicated interpretation of their effects in functional studies. However, the lipids (3-100 microM) also increased agonist potency 30-100 fold in radioligand binding studies.
  
  
  CONCLUSIONS
  This study demonstrates that a diverse range of lipids increase agonist potency at the P2X(7) receptor in functional and binding studies. The broad SAR, including the effect of Triton X-100, suggests this may reflect changes in membrane properties rather than a direct effect on the P2X(7) receptor. Since many of the lipids studied accumulate in disease states they may enhance P2X(7) receptor function under pathophysiological conditions.
authors: Neurology & GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research & Development Limited, New Frontiers Science Park, Harlow, Essex, UK. adm7393@gsk.com
authors: A D
authors: AD
authors: Michel
authors: E
authors: E
authors: Fonfria
mesh_terms: D000255:Adenosine Triphosphate / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D004996:Ethidium / Q000378:metabolism; D005470:Fluorometry; D006801:Humans; D053583:Interleukin-1beta / Q000378:metabolism; D008055:Lipids / Q000737:chemistry / Q000494:pharmacology*; D008244:Lysophosphatidylcholines / Q000737:chemistry / Q000494:pharmacology; D051379:Mice; D017830:Octoxynol / Q000494:pharmacology; D010172:Palmitoylcarnitine / Q000737:chemistry / Q000494:pharmacology; D010767:Phosphorylcholine / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology; D058910:Purinergic P2 Receptor Agonists; D011869:Radioligand Assay; D051381:Rats; D018048:Receptors, Purinergic P2 / Q000235:genetics / Q000378:metabolism*; D058476:Receptors, Purinergic P2X2; D058486:Receptors, Purinergic P2X7; D013110:Sphingosine / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology; D013501:Surface-Active Agents / Q000737:chemistry / Q000494:pharmacology
chemical_list: D053583:Interleukin-1beta; D008055:Lipids; D008244:Lysophosphatidylcholines; C546401:P2RX2 protein, human; C546468:P2RX7 protein, human; C546402:P2rx2 protein, mouse; C546469:P2rx7 protein, mouse; D058910:Purinergic P2 Receptor Agonists; D018048:Receptors, Purinergic P2; D058476:Receptors, Purinergic P2X2; D058486:Receptors, Purinergic P2X7; D013501:Surface-Active Agents; C005356:sphingosine phosphorylcholine; D010767:Phosphorylcholine; D010172:Palmitoylcarnitine; D000255:Adenosine Triphosphate; D017830:Octoxynol; D004996:Ethidium; D013110:Sphingosine; D002118:Calcium
references: Br J Pharmacol. 2007 May;151(1):103-14
references: 17339830
references: J Neurochem. 2007 Sep;102(5):1518-32
references: 17437542
references: Pflugers Arch. 2000 Feb;439(4):495-500
references: 10678748
references: Br J Pharmacol. 2000 May;130(1):167-73
references: 10781013
references: J Biol Chem. 2000 Sep 15;275(37):28398-405
references: 10880510
references: Pflugers Arch. 2000 Dec;441(2-3):200-7
references: 11211104
references: Naunyn Schmiedebergs Arch Pharmacol. 2001 Jun;363(6):639-48
references: 11414659
references: Science. 2001 Jul 27;293(5530):702-5
references: 11474113
references: EMBO J. 2001 Nov 15;20(22):6347-58
references: 11707406
references: Immunity. 2001 Nov;15(5):825-35
references: 11728343
references: J Neurosci. 2002 Apr 15;22(8):3061-9
references: 11943809
references: Biochim Biophys Acta. 2002 May 23;1582(1-3):81-8
references: 12069813
references: Biochim Biophys Acta. 2002 May 23;1582(1-3):178-89
references: 12069827
references: Clin Biochem. 2002 Jul;35(5):411-6
references: 12270773
references: Physiol Rev. 2002 Oct;82(4):1013-67
references: 12270951
references: Mol Pharmacol. 2003 Jun;63(6):1407-16
references: 12761352
references: Curr Med Chem Anticancer Agents. 2003 Sep;3(5):343-53
references: 12871080
references: J Biol Chem. 2003 Sep 26;278(39):37344-51
references: 12869560
references: J Gen Physiol. 2004 May;123(5):599-621
references: 15111647
references: J Clin Invest. 1978 Sep;62(3):546-53
references: 690185
references: Circ Res. 1981 Jan;48(1):1-16
references: 7438341
references: Am J Physiol. 1982 Aug;243(2):H187-95
references: 7114230
references: Pflugers Arch. 1986 Mar;406(3):296-302
references: 2421244
references: Br J Pharmacol. 1987 Oct;92(2):457-68
references: 2445406
references: Pflugers Arch. 1989 Oct;415(1):124-6
references: 2560162
references: J Gen Physiol. 1994 Oct;104(4):645-73
references: 7530766
references: Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5885-9
references: 7597047
references: Br J Dermatol. 1995 Sep;133(3):398-402
references: 8546994
references: Science. 1996 May 3;272(5262):735-8
references: 8614837
references: Pflugers Arch. 1996 Jun;432(2):345-50
references: 8662286
references: Br J Pharmacol. 1997 Aug;121(7):1429-37
references: 9257924
references: Immunity. 1997 Sep;7(3):433-44
references: 9324363
references: Br J Pharmacol. 1997 Nov;122(5):911-7
references: 9384508
references: Atherosclerosis. 1998 Apr;137(2):351-7
references: 9622278
references: J Biol Chem. 1998 Nov 13;273(46):30208-17
references: 9804778
references: Blood. 1998 Nov 15;92(10):3521-8
references: 9808543
references: J Physiol. 1998 Dec 1;513 ( Pt 2):317-30
references: 9806985
references: Kidney Int. 1999 Mar;55(3):1005-10
references: 10027937
references: Nat Neurosci. 1999 Apr;2(4):315-21
references: 10204537
references: Nat Neurosci. 1999 Apr;2(4):322-30
references: 10204538
references: J Lipid Res. 1999 Oct;40(10):1818-26
references: 10508201
references: Med Sci Monit. 2006 Jan;12(1):RA5-16
references: 16369478
references: Biochem Biophys Res Commun. 2006 Mar 24;341(4):1078-87
references: 16460680
references: J Biol Chem. 2006 Feb 24;281(8):4977-82
references: 16368680
references: Eur J Pharmacol. 2006 Mar 18;534(1-3):19-29
references: 16487507
references: Expert Rev Anti Infect Ther. 2006 Apr;4(2):177-85
references: 16597200
references: Trends Pharmacol Sci. 2006 Apr;27(4):211-7
references: 16530853
references: Mol Pharmacol. 2006 Jun;69(6):1975-83
references: 16510558
references: Biochemistry. 2006 Oct 31;45(43):13118-29
references: 17059229
references: EMBO J. 2006 Nov 1;25(21):5071-82
references: 17036048
references: J Recept Signal Transduct Res. 2006;26(5-6):599-610
references: 17118800
references: J Immunol. 2006 Dec 15;177(12):8560-8
references: 17142754
references: Br J Pharmacol. 2007 Feb;150(4):445-54
references: 17211459
references: FEBS Lett. 1999 Nov 5;460(3):467-71
references: 10556518